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 The story of vitamin D is inextricably 
linked with the history of rickets and that 
of medicine itself. In 1903, Niels Ryberg 
Finsen received the Nobel Prize for prov-
ing that concentrated chemical rays may 
exercise benefi cial eff ects in the disfi gur-
ing disease lupus vulgaris through their 
bactericidal eff ects as well as through a 
general stimulating eff ect on the tissues. 
Although at that time vitamin D remained 
undiscovered, this was perhaps the fi rst 
demonstration of the anti-infl ammatory 
and antibacterial eff ect of this vitamin. In 
1921, Alfred Hess, at the annual meeting 
of the American Public Health Associa-
tion, presented the state of the art of the 
prevention and cure of rickets by sun-
light. 1 Although it was debated whether it 
was diet or hygiene that was important for 
the prevention and treatment of rickets, 
Hess recognized that both diet and sun-
light were important for the prevention 
and cure of rickets. Taking clues from the 
seasonal incidence of rickets, which rose 
markedly during spring and winter, he 
exposed babies to the sun  ‘ for 15  min to an 
hour, fi rst the legs, then the arms, and, 
when the weather was mild, the chest and 
back [taking care that] the sun ’ s rays 
[would] impinge directly on the skin, and 
not pass through the window pane  … It 
was found, without exception, that the 
signs of rickets rapidly disappeared under 
this therapy. ’ Alfred Hess was truly a phy-
sician-scientist who not only performed 
patient-oriented research but also stud-
ied this disease in animals. He stated in 
his address to the Child Hygiene Section 
of the American Public Health Associa-
tion,  ‘ we have found the sun treatment 
quite as effi  cacious in the rickets of rats as 
in infantile rickets. If rats are exposed to 
the sun ’ s rays for intervals of 15 – 30  min 
daily, they can by this means regularly be 
protected against rickets, whereas animals 
fed on the same diet, but kept at all times 
in the dark, develop rickets in all 
instances. ’ In 1928, another Nobel Prize 
was awarded to Adolf Otto Reinhold 
Windaus  ‘ for the services rendered 
through his research into the constitution 
of the sterols and their connection with 
the vitamins. ’ The steroid structure 
of vitamin D has now been recognized 
to play various roles in our body, rang-
ing from regulating cell differentia-
tion, immunity, and inflammation to 
main taining calcium homeostasis and 
bone health. 2 
 More recent has been the recognition of 
the interaction of vitamin D with the 
renin – angiotensin system (RAS). 3 Pioneer-
ing discoveries by Li  et al. have demon-
strated that vitamin D is a potent negative 
endocrine regulator of the RAS 4 and 
works predominantly as a suppressor of 
renin biosynthesis. 5 Mice lacking the 
vitamin D receptor have elevated produc-
tion of renin and angiotensin II, leading 
to hypertension and cardiac hypertrophy. 
Vitamin D suppresses renin expression 
independently of its eff ect on calcium 
metabolism as well as independently of 
its eff ect on the volume- and salt-sensing 
mechanisms and the angiotensin II feed-
back regulation. 4 The suppression of 
renin gene transcription has been dem-
onstrated in cell cultures to depend on a 
vitamin D receptor-dependent mecha-
nism. 1,25-Dihydroxyvitamin D also sup-
presses hyperglycemia-induced activation 
of the RAS and transforming growth 
factor-  (TGF-  ) in mesangial and jux-
taglomerular cells. 6 
 Th e new study by Li and colleagues 7 
(this issue) is an extension of prior work 
by the authors that demonstrated that the 
combination of angiotensin receptor 
blockers plus paricalcitol therapy abro-
gates progression of streptozotocin-
induced diabetes. 8 In the current experi-
ment, 7 the authors demonstrated that 
combination therapy is better than sum of 
the parts with respect to progression of 
kidney disease as measured by kidney 
structure (kidney histology) and function 
(albuminuria, serum creatinine) in mice 
with type 2 diabetic nephropathy. A 
strength of this study is that it tested the 
efficacy of vitamin D receptor agonist 
(VDRA) therapy over and above RAS 
blockade. RAS blockers are a standard of 
care for patients with proteinuric chronic 
kidney disease, so this model is clinically 
relevant. Li and colleagues 7 demonstrate 
that the mechanism of renal protection 
appears to be by protection of the podo-
cyte and blockade of the TGF-  system in 
the glomerulus. TGF-  also activates 
interstitial fi broblasts and induces tubular 
epithelial-to-mesenchymal transition. 
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 Vitamin D receptor agonists (VDRAs) inhibit the renin – angiotensin 
system (RAS) and reduce podocyte loss and fibrosis over and above RAS 
blockade. Several studies in humans show that VDRAs are antiproteinuric 
and have the potential to delay the progression of renal disease. 
Whether VDRAs will accomplish this goal among proteinuric patients 
with chronic kidney disease needs to be tested in randomized 
controlled trials. 
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Th us, by blocking TGF-  , VDRAs may 
have the potential to abrogate tubulointer-
stitial fi brosis. Furthermore, VDRAs have 
an anti-inflammatory effect. Taken 
together, these studies suggest that 
VDRAs may protect the kidney through 
their eff ects on both the glomerular and 
the tubulointerstitial compartments 
( Figure 1 ). 
 Although there is strong evidence from 
the studies described above implicating 
the RAS in the mechanism of renal pro-
tection among animals with diabetic 
nephropathy, whether the same holds true 
in humans is unclear. If VDRAs eff ectively 
block the RAS, one would expect them to 
share the side eff ects of RAS blockers, such 
as hyperkalemia, renal failure, and hypo-
tension. Th ese side eff ects are notable by 
their absence in humans. Th us, the mech-
anism that aff ords renal and cardiovascu-
lar protection in humans may not be the 
same as that seen among rodents. 9 Th e 
renoprotective mechanisms in humans 
remain to be discovered. One possibility 
is that VDRAs block the RAS in tissues 
without aff ecting the endocrine system. 
 Nonetheless, there are now at least 
four published studies on the renopro-
tection by VDRAs among patients with 
chronic kidney disease (CKD) not on 
dialysis, which will now be discussed 
further. In the fi rst study, Agarwal  et al. 
reported a reduction in proteinuria 
detected semiquantitatively by dipstick 
with the use of an automated analysis in 
stage 3 and 4 CKD patients with second-
ary hyperparathyroidism who partici-
pated in three randomized controlled 
trials of oral paricalcitol. 10 In this  post hoc 
analysis, reduction of dipstick proteinuria 
occurred despite the use of agents that 
block the RAS. Although previous studies 
report that dipstick proteinuria is a good 
predictor of spot urine protein – creatinine 
ratios, 11 an obvious limitation of this study 
was the method of detection of proteinu-
ria (automated dipstick versus spot 
urinary protein – creatinine or albumin –
 creatinine ratio). 
 Extending the above fi ndings, in the 
fi rst double-blind randomized controlled 
trial, Alborzi  et al. reported 24 patients 
with mostly stage 3 CKD who were ran-
domly allocated to three equal groups to 
receive either 0, 1, or 2   g paricalcitol, a 
VDRA, orally for 1 month. 12 At 1 month, 
the treatment – baseline ratio of high-
 sensitivity C-reactive protein was improved 
with a 2-  g dose of paricalcitol. At 1 month, 
the treatment – baseline ratio of 24-h albu-
min excretion rate was also improved with 
paricalcitol: the ratio was 0.52 (95 % con-
fi dence interval 0.40 – 0.69,  P  <  0.001) with 
a 1-  g dose and 0.54 (95 % confidence 
interval 0.35 – 0.83,  P  =  0.01) with a 2-  g 
dose ( P  <  0.001 for between-group 
changes). Nonetheless, this trial was small, 
with a limited duration of exposure to 
VDRA. Furthermore, all patients had 
low plasma 25-hydroxyvitamin D levels 
in this study; whether nutritional replace-
ment alone could have improved albu-
minuria or inflammation was not 
examined. However, this study suggests 
that paricalcitol may evince reduction in 
albuminuria and inflammation inde-
pendent of its eff ects on hemodynamics 
(measured in this study by glomerular 
fi ltration rate and ambulatory blood pres-
sure monitoring) or parathyroid hormone 
suppression. 
 In a third uncontrolled trial, reported 
from Hong Kong, ten patients with 
biopsy-proven IgA nephropathy and per-
sistent proteinuria despite angiotensin-
converting enzyme inhibition and 
angiotensin II receptor blockade were 
treated with 0.5   g calcitriol twice weekly 
for 12 weeks. 13 Aft er calcitriol treatment, 
there was a signifi cant overall decrease in 
urine protein – creatinine ratio, from 
1.98 ± 0.74 to 1.48 ± 0.81  g / g ( P  =  0.007), 
during the first 6 weeks that persisted 
throughout the study period. No signifi -
cant change in blood pressure or renal 
function was noted. Th ere was a simulta-
neous decrease in serum TGF-  level, and 
the percentage of decrease in serum TGF-
  level signifi cantly correlated with the 
percentage of change in proteinuria 
(Spearman  r  =  0.643;  P  =  0.02). 
 In the fourth study, Fishbane  et al. per-
formed a double-blind randomized con-
trolled trial among 61 patients with CKD 
and proteinuria greater than 400  mg / d, 
assigned equally to either 1   g paricalcitol 
per day or placebo. 14 At baseline, the 
mean urinary protein – creatinine ratios 
were 2.6 and 2.8  g / g in the placebo and 
paricalcitol groups, respectively. At fi nal 
evaluation, the mean ratios were 2.7 and 
2.3, respectively. Changes in protein 
excretion from baseline to last evaluation 
were   +  2.9 % for controls and  – 17.6 % for 
the paricalcitol group ( P  =  0.04). Th us, the 
magnitude of reduction in proteinuria at 
6 months was much less compared with 
that seen at 1 month by Alborzi  et al. 12 
 Finally, the Selective Vitamin D Receptor 
Activator for Albuminuria Lowering 
(VITAL) study tests whether paricalcitol 
persistently reduces albuminuria in diabetic 
subjects already receiving inhibitors of the 
 Figure 1  |  Potential mechanisms through which vitamin D receptor agonists (VDRAs) may 
protect the kidney. Vitamin D receptor agonists (VDRAs) interact with the vitamin D receptor 
in the juxtaglomerular apparatus and inhibit renin synthesis. Blockage of the renin – angiotensin 
system (RAS) can protect glomerular and tubulointerstitial health through a variety of 
mechanisms. In the glomerulus, VDRAs can protect the integrity of the endothelium, podocyte, 
and mesangium. In the tubulointerstitial compartment, VDRAs can block inflammation, reduce 
transforming growth factor-  and therefore epithelial-to-mesenchymal transition (EMT), and 
prevent apoptosis. These effects can be directly mediated by the vitamin D receptor in the tubular, 
mesangial, endothelial, and inflammatory cells or mediated via the RAS. These mechanisms 
suggest that VDRAs can protect the kidney from ongoing scarring and damage. 
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RAS. 15 In this double-blind multicenter 
trial, 281 patients with type 2 diabetic 
nephropathy and albuminuria have been 
randomized equally to 1 or 2   g paricalci-
tol per day or placebo. Th e fi nal results of 
this largest multicenter trial are yet to be 
published. 
 Our present knowledge of vitamin D 
calls for at least maintaining adequate 
stores of vitamin D for bone health and 
perhaps cardiovascular, immunological, 
and renal health among patients with 
CKD. What should be an adequate level of 
vitamin D itself remains poorly defi ned, 
but a 25-hydroxyvitamin D level greater 
than 30 ng / ml is considered adequate. 
Although VDRAs reduce proteinuria, a 
strong surrogate for future renal disease 
progression, whether VDRAs can prolong 
the time to end-stage renal disease has not 
been addressed by any of the existing stud-
ies. Accordingly, whether VDRAs should 
become the standard of care among 
patients with CKD remains to be answered 
by well-designed controlled clinical trials. 
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 Th e health-related quality of life (HRQOL) 
of patients with chronic kidney disease 
(CKD) has recently been the focus of much 
attention. 1 The association of impaired 
HRQOL measures with higher hospitaliza-
tion and mortality rates is well docu-
mented. 2,3 And, importantly, HRQOL 
measures are being viewed as valid end 
points of clinical trials involving the care of 
CKD patients. 1,4 It is in fact now mandated 
that HRQOL be monitored in the United 
States as part of the conditions of coverage 
for end-stage renal disease (ESRD) patients 
by the Centers for Medicare  & Medicaid 
Services. 1 Th e high incidence of clinical 
depression and the striking presence of 
depressive symptoms in CKD patients have 
also been the subject of several recent 
reviews and studies. 3,5 Th ese investigations 
have primarily focused attention on the 
patient with ESRD. 3,5 
 Th e remarkably high prevalence of CKD 
in the general population has been empha-
sized and is provoking much  discussion 
among nephrologists about how to coor-
dinate the care of these patients to slow the 
progression of their CKD, reduce their 
high cardiovascular complication rate, 
manage the various CKD-specifi c comor-
bidities (for example, anemia, CKD – min-
eral and bone disorder, hypertension), 
provide education concerning CKD and 
the implications of ESRD therapy, and 
improve the overall medical care of these 
complex patients. But the impairment of 
the HRQOL of CKD patients not on dialy-
sis has only recently begun to be system-
atically evaluated. 6 – 8 Th ese preliminary 
studies suggest that there is a signifi cant 
 Reassessment of the 
care of the patient with 
chronic kidney disease 
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 The paper by Fischer  et al. focuses attention on the striking prevalence 
of depressive symptoms in non-dialyzed chronic kidney disease 
patients. The presence of depressive symptoms correlated with various 
health-related quality of life measures and economic status. These 
findings suggest that our view of providing care needs to broaden to 
incorporate not only thorough medical care, education, and dietary 
support, but also psychosocial assessments. They also underscore the 
importance of providing this care to those who are most vulnerable. 
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